GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (OSL:CRNA) » Definitions » EV-to-EBIT

Circio Holding ASA (OSL:CRNA) EV-to-EBIT : -0.26 (As of Jun. 10, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Circio Holding ASA EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Circio Holding ASA's Enterprise Value is kr114.19 Mil. Circio Holding ASA's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr-432.68 Mil. Therefore, Circio Holding ASA's EV-to-EBIT for today is -0.26.

The historical rank and industry rank for Circio Holding ASA's EV-to-EBIT or its related term are showing as below:

OSL:CRNA' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.85   Med: -2.63   Max: -0.18
Current: -0.26

During the past 12 years, the highest EV-to-EBIT of Circio Holding ASA was -0.18. The lowest was -9.85. And the median was -2.63.

OSL:CRNA's EV-to-EBIT is ranked worse than
100% of 429 companies
in the Biotechnology industry
Industry Median: 9.38 vs OSL:CRNA: -0.26

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Circio Holding ASA's Enterprise Value for the quarter that ended in Dec. 2023 was kr143.65 Mil. Circio Holding ASA's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr-432.68 Mil. Circio Holding ASA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -301.20%.


Circio Holding ASA EV-to-EBIT Historical Data

The historical data trend for Circio Holding ASA's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Circio Holding ASA EV-to-EBIT Chart

Circio Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.71 -7.50 -3.10 -0.42 -1.34

Circio Holding ASA Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.25 -1.70 -0.42 -0.42 -1.34

Competitive Comparison of Circio Holding ASA's EV-to-EBIT

For the Biotechnology subindustry, Circio Holding ASA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Circio Holding ASA's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Circio Holding ASA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Circio Holding ASA's EV-to-EBIT falls into.



Circio Holding ASA EV-to-EBIT Calculation

Circio Holding ASA's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=114.187/-432.675
=-0.26

Circio Holding ASA's current Enterprise Value is kr114.19 Mil.
Circio Holding ASA's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-432.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Circio Holding ASA  (OSL:CRNA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Circio Holding ASA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-432.675/143.650432
=-301.20 %

Circio Holding ASA's Enterprise Value for the quarter that ended in Dec. 2023 was kr143.65 Mil.
Circio Holding ASA's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-432.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Circio Holding ASA EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Circio Holding ASA's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Circio Holding ASA (OSL:CRNA) Business Description

Traded in Other Exchanges
Address
Vollsveien 19, Lysaker, Oslo, NOR, 1366
Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients.

Circio Holding ASA (OSL:CRNA) Headlines

No Headlines